Clinical Trials Logo

NF1 clinical trials

View clinical trials related to NF1.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05253131 Not yet recruiting - Sarcoma Clinical Trials

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Start date: June 15, 2024
Phase: Phase 2
Study type: Interventional

A multi-institutional open-label phase 1/2 trial of selumetinib in combination with BI and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.